Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019.
Journal
JAMA oncology
ISSN: 2374-2445
Titre abrégé: JAMA Oncol
Pays: United States
ID NLM: 101652861
Informations de publication
Date de publication:
01 Mar 2022
01 Mar 2022
Historique:
pubmed:
31
12
2021
medline:
2
4
2022
entrez:
30
12
2021
Statut:
ppublish
Résumé
The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.
Identifiants
pubmed: 34967848
pii: 2787350
doi: 10.1001/jamaoncol.2021.6987
pmc: PMC8719276
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
420-444Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Organisme : Chief Scientist Office
ID : SCAF/15/02
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : SPHSU17
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00022/2
Pays : United Kingdom
Références
Lancet. 2020 Oct 17;396(10258):1250-1284
pubmed: 32861314
Science. 2020 Jun 19;368(6497):1290
pubmed: 32554570
Popul Health Metr. 2012 Jan 06;10:1
pubmed: 22226226
JAMA Oncol. 2015 Jul;1(4):505-27
pubmed: 26181261
JAMA Oncol. 2017 Apr 01;3(4):524-548
pubmed: 27918777
Lancet Oncol. 2012 Aug;13(8):790-801
pubmed: 22658655
Oncologist. 2019 Dec;24(12):e1371-e1380
pubmed: 31387949
Lancet Oncol. 2018 Oct;19(10):e546-e555
pubmed: 30268693
J Cancer Surviv. 2020 Apr;14(2):235-243
pubmed: 31953645
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Lancet Oncol. 2021 Apr;22(4):e136-e172
pubmed: 33676609
BMJ Glob Health. 2020 Nov;5(11):
pubmed: 33173011
Lancet Oncol. 2021 May;22(5):578-581
pubmed: 33691141
Br J Dermatol. 2012 May;166(5):1069-80
pubmed: 22251204
Ann Glob Health. 2014 Sep-Oct;80(5):412-7
pubmed: 25512156
Nat Med. 2021 Feb;27(2):239-243
pubmed: 33479500
Epidemiol Rev. 2017 Jan 1;39(1):161-169
pubmed: 28472440
Lancet. 2020 Oct 17;396(10258):1223-1249
pubmed: 33069327
Cancer Cell. 2021 Feb 8;39(2):130-131
pubmed: 33465338
Lancet Oncol. 2019 Nov;20(11):e645-e652
pubmed: 31674323
Mol Oncol. 2013 Feb;7(1):1-13
pubmed: 23218182
Lancet Oncol. 2018 Feb;19(2):e85-e92
pubmed: 29413483
J Glob Oncol. 2019 Mar;5:1-8
pubmed: 30908147
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Lancet. 2020 Sep 26;396(10255):918-934
pubmed: 32891217
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Lancet. 2017 Jul 15;390(10091):231-266
pubmed: 28528753
Lancet. 2018 Sep 22;392(10152):1072-1088
pubmed: 30264707
Lancet. 2020 Oct 17;396(10258):1160-1203
pubmed: 33069325
CA Cancer J Clin. 2020 Mar;70(2):105-124
pubmed: 32068901
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
Lancet Oncol. 2020 Aug;21(8):1023-1034
pubmed: 32702310
Lancet. 2016 Dec 10;388(10062):e19-e23
pubmed: 27371184
Lancet. 2017 May 13;389(10082):1885-1906
pubmed: 28390697
JAMA Oncol. 2019 Dec 1;5(12):1749-1768
pubmed: 31560378
Lancet. 2020 Mar 7;395(10226):785-794
pubmed: 31492501
Popul Health Metr. 2010 May 10;8:9
pubmed: 20459720
Lancet Oncol. 2020 Mar;21(3):421-435
pubmed: 32066543
Lancet. 2016 Feb 6;387(10018):e13-e14
pubmed: 26852262
Lancet Oncol. 2015 Oct;16(14):1405-38
pubmed: 26522157
Public Health Rep. 1990 Jul-Aug;105(4):361-7
pubmed: 2116637
Lancet Oncol. 2015 Aug;16(8):e405-13
pubmed: 26248848
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Science. 2021 Jan 1;371(6524):25-27
pubmed: 33384363
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
Lancet. 2021 Jun 19;397(10292):2337-2360
pubmed: 34051883